Objectives: Long-term safety and tolerability of ACC-001 (vanutide cridificar), an antiamyloid-
beta therapeutic vaccine, was evaluated in subjects with mild to moderate Alzheimer’s disease.
Design: Phase 2a extension studies of randomized parent trials were conducted in the United States,
European Union, and Japan.
Methods: Four immunizations of ACC-001 were administered at the same 3 dose levels (3, 10, and 30
μg) to subjects randomized in the parent studies; ACC-001 was administered with QS-21 adjuvant.
Safety, tolerability, and immunogenicity were assessed during active treatment and 6-month follow-up.
Results: ACC-001 + QS-21 was well tolerated in the United States (N=110) and European Union
(N=50), and Japan (N=53) extension studies; safety profile was similar to that observed in the parent
studies, and no new safety signals were identified. Overall, injection site reactions were the most common
adverse event in these studies. Anti-amyloid antibody titers were elicited in all groups, with the
highest titers observed in subjects who received ACC-001 + QS-21 in both the parent and extension
Conclusions: Long-term exposure to ACC-001 + QS-21 was well tolerated in subjects with Alzheimer’s
disease, suggesting that side effects do not pose a principal limitation for anti-amyloid active immunotherapy.
The highest anti-amyloid-beta IgG titers are elicited during long-term therapy with ACC-001
+ QS-21 compared with other regimens.